TY - JOUR
T1 - Donors with Hepatitis B Surface Antigen Positivity
AU - Yavuz, H. Asuman
AU - Tekin, S.
AU - Yuksel, Y.
AU - Ateş, I.
AU - Yucetin, L.
AU - Demir, M.
AU - Uygun, B.
AU - Tuncer, M.
AU - Demirbas, A.
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Objective There is a still controversy among transplantation centers regarding acceptance of hepatitis B surface antigen (HBsAg)-positive donors for renal transplantation. However, some reports show that these donors can be used under a special protocol. In this study, we compared the clinical and biochemical parameters of patients who received kidneys from HBsAg-positive (group 1) versus other living-related kidney donors (group 2). Materials and Methods We retrospectively analyzed the outcomes of 2168 living-related renal transplantations performed between December 2008 and April 2014 at Medical Park Hospital Transplantation Center, Antalya, Turkey. One hundred eleven donors were HbsAg-positive (group 1), and 2057 donors were HbsAg-negative (group 2). Group 1 kidney transplantations were undertaken only if the recipient displayed a hepatitis B antibody titer >10 mIU/mL and donor hepatitis B virus DNA was negative. Results Demographic characteristics; 1-, 2- and 4-year serum creatinine levels; glomerular filtration rates; and liver function test results were similar between the two groups. There were no new hepatitis B virus infections throughout the study period. Acute rejection rates (26/111 in group 1 vs 375/2168 in group 2; P =.887), graft loss (4/111 in group 1 vs 123/2168 in group 2; P =.546), and patient loss (6/111 in group 1 vs 102/2168; P =.132) were similar between the two groups. Conclusion Our study showed that hepatitis B surface antigen positivity was not a contraindication to living-kidney donation.
AB - Objective There is a still controversy among transplantation centers regarding acceptance of hepatitis B surface antigen (HBsAg)-positive donors for renal transplantation. However, some reports show that these donors can be used under a special protocol. In this study, we compared the clinical and biochemical parameters of patients who received kidneys from HBsAg-positive (group 1) versus other living-related kidney donors (group 2). Materials and Methods We retrospectively analyzed the outcomes of 2168 living-related renal transplantations performed between December 2008 and April 2014 at Medical Park Hospital Transplantation Center, Antalya, Turkey. One hundred eleven donors were HbsAg-positive (group 1), and 2057 donors were HbsAg-negative (group 2). Group 1 kidney transplantations were undertaken only if the recipient displayed a hepatitis B antibody titer >10 mIU/mL and donor hepatitis B virus DNA was negative. Results Demographic characteristics; 1-, 2- and 4-year serum creatinine levels; glomerular filtration rates; and liver function test results were similar between the two groups. There were no new hepatitis B virus infections throughout the study period. Acute rejection rates (26/111 in group 1 vs 375/2168 in group 2; P =.887), graft loss (4/111 in group 1 vs 123/2168 in group 2; P =.546), and patient loss (6/111 in group 1 vs 102/2168; P =.132) were similar between the two groups. Conclusion Our study showed that hepatitis B surface antigen positivity was not a contraindication to living-kidney donation.
UR - http://www.scopus.com/inward/record.url?scp=84931476705&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2015.04.014
DO - 10.1016/j.transproceed.2015.04.014
M3 - Article
C2 - 26093707
AN - SCOPUS:84931476705
SN - 0041-1345
VL - 47
SP - 1312
EP - 1314
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 5
ER -
